Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

Am J Health Syst Pharm. 2020 May 19;77(11):835-864. doi: 10.1093/ajhp/zxaa036.

¹ Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, Detroit, MI, School of Medicine, Wayne State University, Detroit, MI, and Detroit Receiving Hospital, Detroit, MI.
² Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA.
³ Albany College of Pharmacy and Health Sciences, Albany, NY, and Stratton VA Medical Center, Albany, NY.
⁴ School of Medicine, Wayne State University, Detroit, MI, and Detroit Receiving Hospital, Detroit, MI.
⁵ Department of Pediatrics, Division of Infectious Diseases, University of California at San Diego, La Jolla, CA, and Rady Children's Hospital San Diego, San Diego, CA.
⁶ Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, and Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
⁷ University of Michigan College of Pharmacy, Ann Arbor, MI.
⁸ University of Southern California School of Pharmacy, Los Angeles, CA.
⁹ University of Minnesota College of Pharmacy, Minneapolis, MN.
¹⁰ University of Illinois College of Pharmacy, Chicago, IL.
¹¹ University of Arkansas for Medical Sciences College of Pharmacy & Arkansas Children's Hospital, Little Rock, AR.
¹² Albany Medical Center Hospital, Albany, NY.

No abstract available

Keywords: nephrotoxicity; pharmacokinetics and pharmacodynamics; target attainment; vancomycin; vancomycin consensus guideline.

MeSH terms